Table 3.
Treatments, and clinical outcomes of different subtypes in patients with COVID-19
| Variable | Mild type (n = 52) | Common type (n = 658) | Severe type (n = 61) | Critical type (n = 17) | Pvalue |
|---|---|---|---|---|---|
| Shock | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (11.8) | < 0.001 |
| Time from illness onset to antiviral treatments (days) | 3.0 (1.0–4.5) | 4.0 (2.0–7.0) | 7.0 (4.0–9.0) | 5.0 (2.0–6.8) | < 0.001 |
| Antiviral treatments | 41 (78.8) | 552 (83.9) | 59 (98.7) | 16 (94.1) | 0.010 |
| Interferon-α inhalation + lopinavir/ritonavir | 9/41 (22.0) | 139/552 (25.2) | 16/59 (27.1) | 1/16 (6.3) | |
| Interferon-α inhalation+ arbidol | 1/41 (2.4) | 33/552 (6.0) | 7/59 (11.9) | 0/16 (0.0) | |
| Interferon-α inhalation + lopinavir/ritonavir+ arbidol | 14/41 (34.1) | 191/552 (34.6) | 23/59 (39.0) | 7/16 (43.8) | |
| Lopinavir/ritonavir + arbidol | 6/41 (14.6) | 62/552 (11.2) | 1/59 (1.7) | 4/16 (25.0) | |
| Lopinavir/ritonavir | 5/41 (12.2) | 60/552 (10.9) | 3/59 (5.1) | 0/16 (0.0) | |
| Arbidol | 2/41 (4.9) | 33/552 (6.0) | 6/61 (10.2) | 0/16 (0.0) | |
| Interferon-α inhalation only | 4/41 (9.8) | 29/552 (5.3) | 2/61 (3.4) | 0/16 (0.0) | |
| others | 0/41 (0.0) | 5/552 (0.9) | 1/61 (1.7) | 4/16 (25.0) | |
| Glucocorticoids | 0 (0.0) | 54 (8.2) | 29 (47.5) | 17 (100.0) | < 0.001 |
| Intravenous immunoglobulin | 0 (0.0) | 24 (3.6) | 26 (42.6) | 12 (70.6) | < 0.001 |
| Extracorporeal membrane oxygenation (ECMO) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Continuous renal-replacement therapy (CRRT) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Clinical outcomes at data cutoff | |||||
| Discharge from hospital | 21 (40.4) | 273 (41.5) | 27 (44.3) | 1 (5.9) | 0.029 |
| Hospitalization | 31 (59.6) | 385 (58.5) | 34 (55.7) | 16 (94.1) | 0.029 |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Data are presented as medians (interquartile ranges, IQR), n (%) and n/N (%)